Skip to main content
Premium Trial:

Request an Annual Quote

Sankyo Subscribes to LifeSpan Database

NEW YORK, July 24-The Japanese pharmaceutical company Sankyo has subscribed to the nuclear receptor module of LifeSpan BioScience's drug target database, LifeSpan said yesterday.


Sankyo will use the database to help in drug target validation for diseases like diabetes, cancer and obesity. It includes immunohistochemical data and public sequence and localization data on more than 2,000 genes.


LifeSpan's database includes information on gene families of interest for drug discovery, and has eight modules. Sankyo also subscribes to the company's G-protein coupled receptor database module.


Nuclear receptors regulate gene activity related to homeostasis, development and differentiation, and have been implicated in cancer, metabolic diseases, rheumatoid arthritis and other disorders.


LifeSpan BioScience is based in Seattle.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.